Validation of Gene Expression-Based Predictive Biomarkers for Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
gene expression signature
locally advanced rectal cancer
meta-analysis
microarray
neoadjuvant chemoradiotherapy
pre-treatment biopsy
predictive biomarker
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Sep 2021
16 Sep 2021
Historique:
received:
02
08
2021
revised:
03
09
2021
accepted:
15
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is widely used for patients with locally advanced rectal cancer. However, response to nCRT varies substantially among patients, highlighting the need for predictive biomarkers that can distinguish non-responsive from responsive patients before nCRT. This study aimed to build novel multi-gene assays for predicting nCRT response, and to validate our signature and previously-reported signatures in multiple independent cohorts. Three microarray datasets of pre-therapeutic biopsies containing a total of 61 non-responders and 53 responders were used as the discovery cohorts to screen for genes that were consistently associated with nCRT response. The predictive values of signatures were tested in a meta-analysis using six independent datasets as the validation cohorts, consisted of a total of 176 non-responders and 99 responders. We identified four genes, including Although this is one of the largest studies addressing the validity of gene expression-based classifiers using pre-treatment biopsies from patients with rectal cancer, our findings do not support their clinically meaningful values to be predictive of nCRT response.
Sections du résumé
BACKGROUND
BACKGROUND
Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is widely used for patients with locally advanced rectal cancer. However, response to nCRT varies substantially among patients, highlighting the need for predictive biomarkers that can distinguish non-responsive from responsive patients before nCRT. This study aimed to build novel multi-gene assays for predicting nCRT response, and to validate our signature and previously-reported signatures in multiple independent cohorts.
METHODS
METHODS
Three microarray datasets of pre-therapeutic biopsies containing a total of 61 non-responders and 53 responders were used as the discovery cohorts to screen for genes that were consistently associated with nCRT response. The predictive values of signatures were tested in a meta-analysis using six independent datasets as the validation cohorts, consisted of a total of 176 non-responders and 99 responders.
RESULTS
RESULTS
We identified four genes, including
CONCLUSIONS
CONCLUSIONS
Although this is one of the largest studies addressing the validity of gene expression-based classifiers using pre-treatment biopsies from patients with rectal cancer, our findings do not support their clinically meaningful values to be predictive of nCRT response.
Identifiants
pubmed: 34572869
pii: cancers13184642
doi: 10.3390/cancers13184642
pmc: PMC8467397
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 16K10545
Références
PLoS One. 2013;8(1):e52589
pubmed: 23326344
Clin Cancer Res. 2011 Jun 15;17(12):4145-54
pubmed: 21467161
J Clin Oncol. 2016 Nov 1;34(31):3773-3780
pubmed: 27432930
Radiat Oncol. 2016 Mar 22;11:50
pubmed: 27005571
Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):834-842
pubmed: 31419511
PLoS One. 2014 Nov 07;9(11):e112189
pubmed: 25380052
Dis Colon Rectum. 2014 Jan;57(1):23-31
pubmed: 24316942
Clin Gastroenterol Hepatol. 2008 Jan;6(1):53-61
pubmed: 18166477
FASEB J. 2021 Jul;35(7):e21719
pubmed: 34110646
Int J Mol Sci. 2020 Sep 24;21(19):
pubmed: 32987896
Cancers (Basel). 2020 Aug 10;12(8):
pubmed: 32784964
Cancers (Basel). 2020 Jul 06;12(7):
pubmed: 32640573
Oncotarget. 2015 Oct 20;6(32):32561-74
pubmed: 26359356
Dis Colon Rectum. 2016 Dec;59(12):1174-1182
pubmed: 27824703
J Natl Cancer Inst. 2017 Dec 1;109(12):
pubmed: 29206996
Br J Surg. 2019 Sep;106(10):1381-1392
pubmed: 31197828
J Natl Compr Canc Netw. 2018 Jul;16(7):874-901
pubmed: 30006429
Clin Cancer Res. 2011 May 1;17(9):3039-47
pubmed: 21224373
J Clin Oncol. 2012 May 20;30(15):1770-6
pubmed: 22493423
Nat Commun. 2016 Aug 26;7:12586
pubmed: 27562646
Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):414-429
pubmed: 32203400
J Pathol. 2018 May;245(1):19-28
pubmed: 29412457
Ann Surg. 2016 Mar;263(3):458-64
pubmed: 24263329
Cancer Biol Ther. 2015;16(8):1160-71
pubmed: 26023803
Cancers (Basel). 2020 Oct 22;12(11):
pubmed: 33105711
J Clin Oncol. 2014 May 20;32(15):1554-62
pubmed: 24752056
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Res Treat. 2016 Jul;48(3):998-1009
pubmed: 26511803
Ann Surg. 2014 Mar;259(3):508-15
pubmed: 23787217
Cancer Res. 2020 Jan 15;80(2):334-346
pubmed: 31704889
J Clin Oncol. 2015 Jun 1;33(16):1797-808
pubmed: 25918296
J Cell Physiol. 2017 Feb;232(2):426-435
pubmed: 27225591
Ann Surg. 2011 Sep;254(3):486-92; discussion 492-3
pubmed: 21865946
Lancet Oncol. 2010 Sep;11(9):835-44
pubmed: 20692872
Ann Transl Med. 2016 Mar;4(6):110
pubmed: 27127763
Clin Cancer Res. 2019 Sep 15;25(18):5561-5571
pubmed: 31253631
Clin Cancer Res. 2020 Oct 1;26(19):5198-5207
pubmed: 32669377
Ann Oncol. 2017 Sep 1;28(9):2160-2168
pubmed: 28911071
Cancers (Basel). 2020 Mar 26;12(4):
pubmed: 32225122
J Clin Oncol. 2005 Mar 20;23(9):1826-38
pubmed: 15774776
Oncotarget. 2017 May 9;8(19):31355-31367
pubmed: 28404895
J Natl Cancer Inst. 2004 Nov 17;96(22):1659-68
pubmed: 15547178
JCI Insight. 2021 Feb 8;6(3):
pubmed: 33400690
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40
pubmed: 28881920
Oncologist. 2013;18(8):909-16
pubmed: 23881989
Dis Colon Rectum. 2007 Sep;50(9):1342-53
pubmed: 17665260
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33106387